Ipsen's growth strategy heavily relies on oncology, with a notable series of business deals aimed at expanding its cancer drug portfolio and pipeline.
The SEC has charged Ipsen's employee Dishant Gupta with insider trading due to his alleged profit from non-public information regarding the $247 million acquisition.
Gupta, as director of data strategy, learned about the market potential for the drug Tazverik, which had FDA approval for treating follicular lymphoma.
The SEC complaint detailed Gupta's suspicious online searches related to an Epizyme buyout just before the acquisition, suggesting insider knowledge of the deal.
Collection
[
|
...
]